

References

S-11

1. Clinical outcomes, perfusion and vascular function in patients with refractory angina and raised lipoprotein (a), treated with lipoprotein apheresis. *ClinicalTrials.gov*. Identifier NCT01796912. October 2013.
2. Fridey JL, Kaplan AA. Indications for therapeutic plasma exchange. Available from: *Up-To-Date*.
3. Huang C, Chang C, Huang C, et al. Using oxidized low-density lipoprotein autoantibodies to predict restenosis after balloon angioplasty in patients with acute myocardial infarction. *Plos One*. 2013;8(10):e74726.
4. Schrier S. Acquired pure red cell aplasia in the adult. *Up-To-Date*. October 28, 2013.
5. U.S. Food and Drug Administration. FDA approves new pediatric use for Liposorber *Apheresis System*. October 2013.
6. Fridey J, Kaplan A. Therapeutic plasma exchange: Indications. Available from: *Up-to-Date*. Accessed December 2013.
7. Schwartz J, Winters J, Padmanadhan A, et al. Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach from the writing committee of the American Society for Apheresis: The sixth special issue. *Journal of Clinical Apheresis*. 2013;28(3):145-284.
8. Tavori H, Giunzioni I, Linton M, et al. Loss of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) after lipoprotein apheresis. *Circulation Research*. 2013;113(12):1290-1295.
9. Hertl M, Rudiger E. Management of refractory pemphigus vulgaris and pemphigus foliaceus. *Up-To-Date*. 2013.
10. Diakoumakou O, Hatzigeorgiou G, Kolovou G, et al. Severe/Extreme Hypertriglyceridemia and LDL Apheretic Treatment: Review of the Literature, Original Findings. *Cholesterol*. 2014;2014:109263. Ipswich, MA.
11. National Comprehensive Cancer Network. *NCCN clinical practice guidelines in oncology: Multiple Myeloma*. Version 1. 2015.
12. Schwartz, J. Clinical Applications of Therapeutic Apheresis: An Evidence Based Approach. 6th Edition. *Journal of Clinical Apheresis*. 2013;28(3):145-284.
13. Heigl, F. Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease. *Clin Res Cardiol Suppl*. 2015;10:8–13.
14. Varga, V. Impact of selective LDL apheresis on serum chemerin levels in patients with hypercholesterolemia. *Lipids in Health and Disease*. 2016;15:1-7.
15. Winters, J. National Heart, Lung, and Blood Institute State of the Science Symposium in Therapeutic Apheresis—Therapeutic Apheresis in Cardiovascular Disease. *Journal of Clinical Apheresis*. 2015;30: 183-187.
16. Su Y, Chiu W, Hsu C, Chen J, Ng H. Lower In-Hospital Mortality with Plasma Exchange than Plasmapheresis in a Subgroup Analysis of 374 Lupus Patients. *Biomed Research International*. 2018;1-8.